Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Lowered by Leerink Partners

Leerink Partners lowered shares of Agios Pharmaceuticals (NASDAQ:AGIO) from an outperform rating to a market perform rating in a research report report published on Friday morning, Marketbeat.com reports. Leerink Partners currently has $56.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $60.00.

Several other equities analysts have also issued reports on AGIO. JPMorgan Chase & Co. restated a neutral rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. The Goldman Sachs Group upped their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a research note on Tuesday, June 4th. StockNews.com cut shares of Agios Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. Royal Bank of Canada restated an outperform rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $52.50.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $44.43 on Friday. Agios Pharmaceuticals has a fifty-two week low of $19.80 and a fifty-two week high of $53.28. The firm has a market capitalization of $2.52 billion, a P/E ratio of -7.03 and a beta of 0.75. The company’s 50 day simple moving average is $45.61 and its 200 day simple moving average is $39.92.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the company earned ($1.51) EPS. Sell-side analysts expect that Agios Pharmaceuticals will post -4.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The disclosure for this sale can be found here. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AGIO. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth $40,000. NEOS Investment Management LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $210,000. North Star Asset Management Inc. acquired a new stake in Agios Pharmaceuticals in the second quarter valued at $216,000. Finally, XTX Topco Ltd bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $230,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.